Rigel Pharmaceuticals (RIGL) Gains from Sales and Divestitures (2022 - 2025)
Rigel Pharmaceuticals (RIGL) recorded quarterly Gains from Sales and Divestitures of $143691.0 in Q3 2025, little changed quarter-over-quarter from $143691.0 in Q2 2025, and up 108.53% on a YoY basis from $68908.0 in Q3 2024.
Rigel Pharmaceuticals (RIGL) Gains from Sales and Divestitures (2022 - 2025) Analysis & Trends
Rigel Pharmaceuticals' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $143691.0 for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Rigel Pharmaceuticals | 603.18 Mn | 456.49 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 143,691.00 |
| Sep 30, 2025 | 143,691.00 |
| Jun 30, 2025 | 143,691.00 |
| Jun 30, 2025 | 143,691.00 |
| Mar 31, 2025 | 125,783.00 |
| Mar 31, 2025 | 125,783.00 |
| Sep 30, 2024 | 68,908.00 |
| Sep 30, 2024 | 68,908.00 |
| Jun 30, 2024 | 66,408.00 |
| Jun 30, 2024 | 66,408.00 |
| Mar 31, 2024 | 489,992.00 |
| Mar 31, 2024 | 489,992.00 |
| Sep 30, 2023 | 435,006.00 |
| Sep 30, 2023 | 435,006.00 |
| Jun 30, 2023 | 435,006.00 |
| Jun 30, 2023 | 435,006.00 |
| Mar 31, 2023 | 266,256.00 |
| Mar 31, 2023 | 266,256.00 |
| Sep 30, 2022 | 203,750.00 |
| Sep 30, 2022 | 203,750.00 |